Table 2.
Second-line (2L) treatment attrition and reasons for discontinuation
| All (n = 312) |
T-based 2L (n = 116) |
|
|---|---|---|
| Ongoing 2L at end of follow-up, n (%) | 38 (12) | 21 (18) |
| Discontinued 2L, n (%) | 274 (88) | 95 (82) |
| Initiated 3La | 197 (72) | 75 (79) |
| Ongoing 2L at the time of deatha | 7 (2) | 1(1) |
| Died after 2L, prior to 3L starta | 49 (18) | 11 (12) |
| No further treatment during follow-upa | 21 (8) | 8 (8) |
| Most common reasons for discontinuation, n (%) | ||
| Progression/worsening of cancera | 128 (47) | 39 (41) |
| Intolerance/toxicity in absence of progressiona | 47 (17) | 22 (23) |
| End of planned therapya | 25 (9) | 19 (20) |
aDistribution is based on patients who discontinued 2L therapy